Lars Bastholt

31.1k total citations · 4 hit papers
183 papers, 8.3k citations indexed

About

Lars Bastholt is a scholar working on Oncology, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Lars Bastholt has authored 183 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Oncology, 46 papers in Molecular Biology and 38 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Lars Bastholt's work include Cancer Immunotherapy and Biomarkers (42 papers), Thyroid Cancer Diagnosis and Treatment (38 papers) and Cutaneous Melanoma Detection and Management (33 papers). Lars Bastholt is often cited by papers focused on Cancer Immunotherapy and Biomarkers (42 papers), Thyroid Cancer Diagnosis and Treatment (38 papers) and Cutaneous Melanoma Detection and Management (33 papers). Lars Bastholt collaborates with scholars based in Denmark, France and Germany. Lars Bastholt's co-authors include Martin Schlumberger, Olfred Hansen, Steven I. Sherman, Lena Specht, Hanne Sand Hansen, Barbara Jarząb, Furio Pacini, Christelle de la Fouchardière, Rossella Elisei and Henrik Schmidt and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Lars Bastholt

180 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

2014 1.2k citations Marcia S. Brose, Barbara Jarząb et al. profile →
Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial

2003 481 citations Jens Overgaard, Lars Bastholt et al. profile →
Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline

2015 371 citations Mark R. Middleton, Lars Bastholt et al. European Journal of Cancer profile →
Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline

2015 340 citations Claus Garbe, Mark R. Middleton et al. European Journal of Cancer profile →

Peers

Countries citing papers authored by Lars Bastholt

Since Specialization

Citations

This map shows the geographic impact of Lars Bastholt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Bastholt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Bastholt more than expected).

Fields of papers citing papers by Lars Bastholt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Bastholt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Bastholt. The network helps show where Lars Bastholt may publish in the future.

Co-authorship network of co-authors of Lars Bastholt

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Bastholt. A scholar is included among the top collaborators of Lars Bastholt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Bastholt. Lars Bastholt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Single agent anti-PD-1 versus combined BRAF and MEK inhibitors upfront in metastatic or unresectable BRAF V600 mutated melanoma - A EUMelaReg real world evidence study 2025 ·(unknown), (unknown), Nethanel Asher, (unknown), J.B.A.G. Haanen, (unknown), (unknown), (unknown), (unknown), Enrique Espinosa, (unknown), Lars Bastholt	1
2	Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility 2025 ·Acta Oncologica ·(unknown), (unknown), Lars Bastholt, (unknown), Henrik Schmidt, (unknown)	2
3	Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study 2024 ·Supportive Care in Cancer ·(unknown), (unknown), (unknown), (unknown), Carsten Brink, Thomas Heiberg Brix, Eva Ellebæk, Inge Marie Svane, (unknown), Charlotte Aaquist Haslund, (unknown), Henrik Schmidt, (unknown), Lars Bastholt, Christina H. Ruhlmann	1
4	Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study 2024 ·European Journal of Cancer ·(unknown), Christian Rønn Hansen, Eva Ellebæk, Henrik Schmidt, Charlotte Aaquist Haslund, Christina H. Ruhlmann, Lars Bastholt	3
5	Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy 2024 ·Endocrine Related Cancer ·Marcia S. Brose, Jaume Capdevila, Rossella Elisei, Lars Bastholt, Dagmar Führer‐Sakel, Sophie Leboulleux, Iwao Sugitani, Matthew H. Taylor, Zhuoying Wang, Lori J. Wirth, Francis P. Worden, John Bernard, (unknown), (unknown), Shiguang Liu, Martin Schlumberger	4
6	Health care and socioeconomic costs for long-term survivors after implementation of checkpoint-inhibitors and targeted agents for metastatic melanoma 2023 ·European Journal of Cancer ·(unknown), Jakob Kjellberg, Rikke Ibsen, Lars Bastholt, Henrik Schmidt, Inge Marie Svane	2
7	Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapies 2023 ·European Journal of Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), Charlotte Aaquist Haslund, Henrik Schmidt, Lars Bastholt, Inge Marie Svane, Eva Ellebæk, Marco Donia	6
8	1156P Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome 2023 ·Annals of Oncology ·Eva Ellebæk, (unknown), (unknown), Rikke B. Holmstroem, Marco Donia, Charlotte Aaquist Haslund, Henrik Schmidt, Lars Bastholt, Christina H. Ruhlmann, Inge Marie Svane	3
9	Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients 2023 ·Annals of Surgical Oncology ·(unknown), (unknown), Annette H. Chakera, Helle Westergren Hendel, Eva Ellebæk, Inge Marie Svane, (unknown), (unknown), (unknown), (unknown), Lars Bastholt, Christoffer Johansen, Pernille Envold Bidstrup, Lisbet Rosenkrantz Hölmich	5
10	PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma 2023 ·European Journal of Cancer ·Eva Ellebæk, Shawez Khan, Lars Bastholt, Henrik Schmidt, Charlotte Aaquist Haslund, Marco Donia, Inge Marie Svane	18
11	Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA) 2022 ·Journal of Clinical Oncology ·Alan L. Ho, Marek Dedecjus, Lori J. Wirth, R. Michael Tuttle, William B. Inabnet, Jan Tennvall, Fernanda Vaisman, Lars Bastholt, Andrew G. Gianoukakis, Patrice Rodien, Ralf Paschke, Rossella Elisei, David Viola, Karen So, Danielle Carroll, (unknown), (unknown), James A. Fagin, (unknown)	37
12	The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma 2022 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), (unknown), (unknown), Peter Grupe, Søren Hess, Paw Christian Holdgaard, Lars Bastholt, Oke Gerke, Malene Grubbe Hildebrandt	10
13	Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study 2021 ·Cancers ·(unknown), (unknown), Lars Bastholt, Inge Marie Svane, Marco Donia, A.A. Luczak, Christina H. Ruhlmann, (unknown), Ulrich Koehler, (unknown), Eva Ellebæk, Charlotte Aaquist Haslund, Henrik Schmidt	3
14	1919P Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study (NCT01788982) 2020 ·Annals of Oncology ·K. Newbold, (unknown), Baktiar Hasan, Laura D. Locati, Yann Godbert, Christelle de la Fouchardière, Lars Bastholt, Martin Faßnacht, Nicole Reed, Yassine Lalami, C. Chougnet, Claire Schvartz, Ellen Kapiteijn, M Schlumberger, Ward Sents, Nicolas Sauvé, Sophie Leboulleux	1
15	Immunterapi er kræftbehandling med en helt ny bivirkningsprofil 2018 ·Ugeskrift for Læger ·(unknown), (unknown), Inge Marie Svane, Henrik Schmidt, Lars Bastholt	1
16	Risk of recurrence from papillary thyroid microcarcinoma by method of discovery 2015 ·VBN Forskningsportal (Aalborg Universitet) ·Stefano Christian Londero, Annelise Krogdahl, Lars Bastholt, Jens Overgaard, Christoffer Holst Hahn, Henrik Baymler Pedersen, Jens Bentzen, Sten Schytte, P. Christiansen, Christian Godballe	1
17	Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma 2011 ·Clinical Cancer Research ·John M. Kirkwood, Lars Bastholt, Caroline Robert, Jeff Sosman, James Larkin, Peter Hersey, Mark R. Middleton, Mireille Cantarini, Victoria Zazulina, Karin Kemsley, Reinhard Dummer	218
18	CHEK21100delC and Risk of Malignant Melanoma: Danish and German Studies and Meta-Analysis 2011 ·Journal of Investigative Dermatology* ·Maren Weischer, Ida M. Heerfordt, Stig E. Bojesen, Thomas Eigentler, Claus Garbe, Martin Röcken, Lisbet Rosenkrantz Hölmich, Henrik Schmidt, (unknown), Lars Bastholt, Børge G. Nordestgaard	24
19	Vandetanib In Locally Advanced Or Metastatic Differentiated Thyroid Cancer (Papillary Or Follicular; Dtc): A Randomized, Double-Blind Phase Ii Trial 2010 ·Annals of Oncology ·Sophie Leboulleux, Lars Bastholt, Thomas Krause, Christelle de la Fouchardière, Jan Tennvall, Ahmad Awada, Joaquín Marchena‐Gómez, (unknown), Muriel Licour, Martin Schlumberger	17
20	Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer 2009 ·Journal of Clinical Oncology ·Martin Schlumberger, Rossella Elisei, Lars Bastholt, Lori J. Wirth, Renato Martins, Laura D. Locati, Barbara Jarząb, Furio Pacini, Chantal Daumerie, Jean-Pierre Droz, Michael Eschenberg, Yu-Nien Sun, Todd Juan, Daniel E. Stepan, Steven I. Sherman	257

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact